Human medicines European public assessment report (EPAR): Eyluxvi, aflibercept, Date of authorisation: 15/09/2025, Status: Authorised

The approval of Eyluxvi, a biosimilar to aflibercept, for various eye conditions provides healthcare professionals with a more affordable treatment option for patients with wet age-related macular degeneration, diabetic macular edema, and other related conditions. This expands access to effective ophthalmic treatments, potentially improving patient outcomes and healthcare delivery.